SCHEMBL29529965

SCHEMBL29529965

N#Cc1ccncc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190868 1.00
SCHEMBL328913 0.82
SCHEMBL29546988 0.78 HTT (0.50)
SCHEMBL20043 0.78 HTT (0.50)
SCHEMBL5700051 0.77
SCHEMBL20448758 0.77
SCHEMBL15539832 0.77
SCHEMBL21535943 0.74 GAA (0.43)
SCHEMBL17558980 0.74 HTT (0.51)
SCHEMBL166316 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Scorpion Therapeutics, Inc. (US) 2023-08-02 EP disclosed
EP-4003339-A2 DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE Sanford Burnham Prebys Medical Discovery Institute (US) 2022-06-01 EP disclosed
WO-2022066734-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER SCORPION THERAPEUTICS, INC. (US) 2022-03-31 WO disclosed